Literature DB >> 10452973

Distribution fate and mechanism of immune modulation following mucosal delivery of plasmid DNA encoding IL-10.

S Chun1, M Daheshia, S Lee, S K Eo, B T Rouse.   

Abstract

DNA vaccination has been widely studied in several models of vaccination and in the treatment of inflammatory diseases, even though the mechanism involved is still unclear. This report demonstrates that mucosal administration of plasmid DNA leads to rapid and widespread distribution around the body. Dissemination likely occurred via the bloodstream because plasmid DNA was present in blood plasma. The plasmid DNA was also detectable in several tissues including draining lymph nodes, spleen, liver, bone marrow, and even the dermis of ear pinnae. Except for the site of administration, plasmid DNA was no longer detectable in tissues after 3 wk postadministration. RNA and protein expression was also found in the tissues and bloodstream. Animals previously primed by HSV infection and subsequently given IL-10 DNA via the nasal mucosa, showed diminished Ag-induced delayed type hypersensitivity reactions for up to 5 wk posttreatment. The mechanism of modulation involved diminished the Ag-specific proliferation and production of Th1 cytokines. The Ag-specific silencing effects persisted beyond the duration of detectable plasmid encoded protein and was maintained upon adoptive transfer of T cells into a plasmid-free environment. The silenced T cells were not a source of IL-10, and their anergic state was reversible by exposure to Ag in the presence of exogenous IL-2.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10452973

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  Type I interferons and herpes simplex virus infection: a naked DNA approach as a therapeutic option?

Authors:  S Noisakran; D J Carr
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Neonates mount robust and protective adult-like CD8(+)-T-cell responses to DNA vaccines.

Authors:  Jie Zhang; Nicole Silvestri; J Lindsay Whitton; Daniel E Hassett
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus.

Authors:  N H Gruener; F Lechner; M C Jung; H Diepolder; T Gerlach; G Lauer; B Walker; J Sullivan; R Phillips; G R Pape; P Klenerman
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Enhanced brain targeting efficiency of intranasally administered plasmid DNA: an alternative route for brain gene therapy.

Authors:  In-Kwon Han; Mi Young Kim; Hyang-Min Byun; Tae Sun Hwang; Jung Mogg Kim; Kwang Woo Hwang; Tae Gwan Park; Woon-Won Jung; Taehoon Chun; Gil-Jae Jeong; Yu-Kyoung Oh
Journal:  J Mol Med (Berl)       Date:  2006-11-07       Impact factor: 4.599

5.  Immunomodulation by topical particle-mediated administration of cytokine plasmid DNA suppresses herpetic stromal keratitis without impairment of antiviral defense.

Authors:  Dirk Bauer; Mengji Lu; Susanne Wasmuth; Haiping Li; Yanning Yang; Michael Roggendorf; Klaus Peter Steuhl; Arnd Heiligenhaus
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-07-27       Impact factor: 3.117

6.  Distribution and expression of recombinant plasmid encoding chicken interleukin-2.

Authors:  Z Q You; L Yu; C Z Zhang; L Li; M J Lu; Z J Mao; Y Liu; W Y Chu
Journal:  Vet Res Commun       Date:  2006-12-20       Impact factor: 2.459

7.  Modulation of immunity against herpes simplex virus infection via mucosal genetic transfer of plasmid DNA encoding chemokines.

Authors:  S K Eo; S Lee; S Chun; B T Rouse
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

8.  Induction of in vivo resistance to Mycobacterium avium infection by intramuscular injection with DNA encoding interleukin-18.

Authors:  S H Kim; D Cho; T S Kim
Journal:  Immunology       Date:  2001-02       Impact factor: 7.397

9.  Tissue distribution of a plasmid DNA encoding Hsp65 gene is dependent on the dose administered through intramuscular delivery.

Authors:  A A M Coelho-Castelo; A P Trombone; R S Rosada; R R Santos; V L D Bonato; A Sartori; C L Silva
Journal:  Genet Vaccines Ther       Date:  2006-01-30

10.  Treatment of experimental (Trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-beta1 plasmid: TGF-beta1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor beta2 chain downregulation.

Authors:  A Kitani; I J Fuss; K Nakamura; O M Schwartz; T Usui; W Strober
Journal:  J Exp Med       Date:  2000-07-03       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.